Trends in End-of-Life Care in Women With Metastatic Breast Cancer
A recent analysis of insurance claims data revealed trends in ED visits, ICU visits, hospitalizations, and antineoplastic treatment at the end of life in this population.
Diagnosis & Disease Information
Patient, Provider Perspectives on Incorporating Prognosis into Shared Decision Making for Women With mBC
In this study, nurse participants emphasized the connection between the early delivery of prognostic information and the optimal delivery of palliative care.
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
The FDA has approved neratinib (Puma Biotechnology), a kinase inhibitor, in combination with capecitabine, for the treatment of adult patients with advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received 2 or more prior anti-HER2 based regimens in the metastatic setting.
Tucatinib Gets Priority Review for Locally Advanced or Metastatic HER2-Positive Breast Cancer
The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.
Patient-Driven Solutions May Lead to Greater Metastatic Breast Cancer Clinical Trial Participation
More patients living with metastatic breast cancer reportedly would be willing to participate in clinical trials if some changes were made.
Germline Testing Should Be Routinely Conducted in Patients With Metastatic Breast Cancer
High prevalence of pathogenic/likely pathogenic variants supports wider testing.
CDK4/6 Inhibitors Should Be Standard First-Line Treatment for Metastatic HR+ Breast Cancer, Concludes Expert
Emerging overall survival data show a benefit of this type of drug across a variety of patient subgroups.
Personalized Therapy Shows Promise in Metastatic Breast Cancer
A personalized therapy can mediate complete durable cancer regression, according to study results.
cfDNA Profiling Prognostic for Survival in Metastatic Triple-Negative Breast Cancer
Despite other clinicopathologic factors, patients with a tumor fraction of 10% or greater were more than twice as likely to pass away as those with a fraction of less than 10%.
Quality of Life During Maintenance Therapy Better With Lower Dose, More Often
Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.
- Loading...
Loading...
Next post in SABCS 2017
Loading... 
Loading...